VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as directors of the Company. The Company would like to thank Mr. Thoresen and Mr. Damouni for their contributions to the Company.
The Company is pleased to also announce that Joseph Meagher, the Chief Financial Officer of the Company, has been appointed as a director of the Company to fill one of the vacancies.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next‐generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low‐cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +1 780-818-6422
| Last Trade: | C$0.40 |
| Daily Change: | -0.03 -6.98 |
| Daily Volume: | 184,660 |
| Market Cap: | C$45.360M |
January 21, 2025 December 19, 2024 December 09, 2024 November 25, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
